Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
▼
$0.00
$1K-1.06373 shs92 shs
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
+∞
$0.00
$0.00
▼
$0.00
$3K1.077,862 shs100 shs
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
$0.00
-75.0%
$0.00
$0.00
▼
$0.02
$1K2.915,694 shs3,500 shs
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
$0.00
$0.00
▼
$0.05
$4K1.94N/AN/A
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%+200.00%-40.00%+200.00%-70.00%
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%0.00%
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
-75.00%-75.00%0.00%-75.00%-66.67%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
▼
$0.00
$1K-1.06373 shs92 shs
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
+∞
$0.00
$0.00
▼
$0.00
$3K1.077,862 shs100 shs
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
$0.00
-75.0%
$0.00
$0.00
▼
$0.02
$1K2.915,694 shs3,500 shs
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
$0.00
$0.00
▼
$0.05
$4K1.94N/AN/A
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%+200.00%-40.00%+200.00%-70.00%
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%0.00%
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
-75.00%-75.00%0.00%-75.00%-66.67%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00
N/AN/AN/A
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
0.00
N/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$1.00M0.00N/AN/AN/A∞
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
N/AN/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
-$18M-$0.10N/AN/AN/AN/AN/AN/AN/A
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
-$35.81M-$8.83N/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest CALA, EFTR, SPHS, and CMRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/17/2026N/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$5.5189N/AN/AN/A$0.48 millionN/A
11/17/2026N/A
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
-$6.3960N/AN/AN/A$0.10 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/AN/AN/A
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
N/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/A
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
57.67%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/A

Insider Ownership

CompanyInsider Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
8.90%
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
4.70%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
603.86 millionN/ANot Optionable
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
230.74 million28.00 millionNot Optionable
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
104.70 million4.48 millionNo Data
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
635.55 millionN/ANot Optionable

Recent News About These Companies

Sophiris Bio Inc Stock Price History
Sophiris Bio Inc (SPHS)
Wisr AI Systems Inc. Announces Closing of Amalgamation
Best Louisiana High Schools
BLTE - Belite Bio, Inc
Bio-Reference Laboratories
Sophiris Bio Inc. Registered Sh (BFF1.SG)
Pennsylvania Gov.-elect Josh Shapiro biography
Weapons news
Calithera Biosciences stock logo

Calithera Biosciences OTCMKTS:CALA

$0.0003 0.00 (0.00%)
As of 11/16/2026

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Comera Life Sciences stock logo

Comera Life Sciences NASDAQ:CMRA

$0.0001 +0.00 (+∞)
As of 09:30 AM Eastern

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

eFFECTOR Therapeutics stock logo

eFFECTOR Therapeutics OTCMKTS:EFTR

$0.0002 0.00 (-75.00%)
As of 11:10 AM Eastern

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Sophiris Bio stock logo

Sophiris Bio OTCMKTS:SPHS

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.